. "Investigated for use/treatment in HIV infection."@en . . . . . . . . . . . . . . . . "500287-72-9"@en . "TMC278 is an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) under development. TMC278 is a diarylpyrimidine derivative, a new series of NNRTIs which show high intrinsic activity against both wild-type HIV-1 and against HIV strains harboring resistance inducing mutations."@en . . . "TMC278"@en . . . "# Boone LR: Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16499282"@en . . . . . "investigational"@en . . . . . . . . . "38 hours"@en .